Relmada Therapeutics Added to Russell 2000 and 3000 Indexes
Event summary
- Relmada Therapeutics added to the Russell 2000 and Russell 3000 indexes effective June 26, 2026.
- Russell 3000 tracks the 3,000 largest U.S. publicly traded companies, representing ~98% of investable U.S. equity market.
- Russell 2000 measures performance of 2,000 small-cap U.S. companies.
- Inclusion follows semi-annual reconstitution process used by institutional investors for benchmarking.
The big picture
Inclusion in the Russell indexes signals growing institutional interest in Relmada as a small-cap biotech player. The move comes amid increasing demand for exposure to innovative oncology and CNS therapies, with the Russell 2000 serving as a key benchmark for small-cap performance. This inclusion may attract passive fund inflows while raising Relmada's profile among active managers benchmarked against these indexes.
What we're watching
- Clinical Progress
- How NDV-01 Phase 2 data will impact Relmada's valuation and investor confidence.
- Capital Efficiency
- Whether Relmada can sustain its well-capitalized position through ongoing clinical trials.
- Regulatory Pathway
- The pace at which FDA agreements will be secured for NDV-01 and sepranolone development.
Related topics